
|Articles|October 1, 2001
Verteporfin for injection
The FDA has approved Visudyne (verteporfinfor injection) therapy for the treatment of predominantly classic subfovealchoroidal neovascularization (CNV) caused by pathologic myopia and presumedocular histoplasmosis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















